Literature DB >> 22591361

HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Peter S Silverstein1, Ankit Shah, James Weemhoff, Santosh Kumar, D P Singh, Anil Kumar.   

Abstract

HIV-1 infection is a global public health problem with more than 34 million people living with HIV infection. Although great strides have been made in treating this epidemic with therapeutic agents, the increase in patient life span has been coincident with an increase in the prevalence of HIV-associated neurocognitive disorders (HAND). HAND is thought to result from the neurotoxic effects of viral proteins that are shed from HIV-infected microglial cells. One of the primary neurotoxins responsible for this effect is the HIV-1 glycoprotein gp120. Exposure of neurons to gp120 has been demonstrated to cause apoptosis in neurons, as well as numerous indirect effects such as an increase in inflammatory cytokines, an increase in oxidative stress, and an increase in permeability of the blood-brain barrier. In many patients, the use of drugs of abuse (DOA) exacerbates the neurotoxic effects of gp120. Cocaine, methamphetamine and morphine are three DOAs that are commonly used by those infected with HIV-1. All three of these DOAs have been demonstrated to increase oxidative stress in the CNS as well as to increase permeability of the blood-brain barrier. Numerous model systems have demonstrated that these DOAs have the capability of exacerbating the neurotoxic effects of gp120. This review will summarize the neurotoxic effects of gp120, the deleterious effects of cocaine, methamphetamine and morphine on the CNS, and the combined effects of gp120 in the context of these drugs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22591361      PMCID: PMC4086306          DOI: 10.2174/157016212802138724

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  140 in total

1.  Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro.

Authors:  B Viviani; E Corsini; M Binaglia; C L Galli; M Marinovich
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment.

Authors:  M R Gluck; L Y Moy; E Jayatilleke; K A Hogan; L Manzino; P K Sonsalla
Journal:  J Neurochem       Date:  2001-10       Impact factor: 5.372

3.  Induction of nuclear factor-kappaB in nucleus accumbens by chronic cocaine administration.

Authors:  E Ang; J Chen; P Zagouras; H Magna; J Holland; E Schaeffer; E J Nestler
Journal:  J Neurochem       Date:  2001-10       Impact factor: 5.372

4.  Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis.

Authors:  Kristin E Larsen; Edward A Fon; Teresa G Hastings; Robert H Edwards; David Sulzer
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

5.  Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.

Authors:  Verónica Sandoval; Evan L Riddle; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

6.  Morphine regulates gene expression of alpha- and beta-chemokines and their receptors on astroglial cells via the opioid mu receptor.

Authors:  Supriya D Mahajan; Stanley A Schwartz; Thomas C Shanahan; Ram P Chawda; Madhavan P N Nair
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

7.  Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication.

Authors:  Amber D Steele; Earl E Henderson; Thomas J Rogers
Journal:  Virology       Date:  2003-04-25       Impact factor: 3.616

8.  A single methamphetamine administration rapidly decreases vesicular dopamine uptake.

Authors:  Jeffrey M Brown; Evan L Riddle; Verónica Sandoval; Raul K Weston; Jarom E Hanson; Michael J Crosby; Yvette V Ugarte; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

Review 9.  Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system.

Authors:  Françoise Lazarini; To Nam Tham; Philippe Casanova; Fernando Arenzana-Seisdedos; Monique Dubois-Dalcq
Journal:  Glia       Date:  2003-04-15       Impact factor: 7.452

10.  Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine.

Authors:  J Turchan; C Anderson; K F Hauser; Q Sun; J Zhang; Y Liu; P M Wise; I Kruman; W Maragos; M P Mattson; R Booze; A Nath
Journal:  BMC Neurosci       Date:  2001-03-02       Impact factor: 3.288

View more
  37 in total

1.  Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study.

Authors:  Angela Matinella; M Lanzafame; M A Bonometti; A Gajofatto; E Concia; S Vento; S Monaco; S Ferrari
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

2.  Curcumin Increases HSP70 Expression in Primary Rat Cortical Neuronal Apoptosis Induced by gp120 V3 Loop Peptide.

Authors:  Chenglai Xia; Yantao Cai; Shuhua Li; Jie Yang; Guohong Xiao
Journal:  Neurochem Res       Date:  2015-08-21       Impact factor: 3.996

3.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

4.  HIV-1 gp120 Glycoprotein Interacting with Dendritic Cell-specific Intercellular Adhesion Molecule 3-grabbing Non-integrin (DC-SIGN) Down-Regulates Tight Junction Proteins to Disrupt the Blood Retinal Barrier and Increase Its Permeability.

Authors:  Yi-Wen Qian; Chuan Li; Ai-Ping Jiang; Shengfang Ge; Ping Gu; Xianqun Fan; Tai-Sheng Li; Xia Jin; Jian-Hua Wang; Zhi-Liang Wang
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

5.  Target of HIV-1 Envelope Glycoprotein gp120-Induced Hippocampal Neuron Damage: Role of Voltage-Gated K(+) Channel Kv2.1.

Authors:  Qing Zhu; Xu Song; Jing Zhou; Yixin Wang; Jianxun Xia; Wenyi Qian; Jingying Zhu; Rong Gao; Jun Wang; Hang Xiao
Journal:  Viral Immunol       Date:  2015-09-22       Impact factor: 2.257

6.  Transcriptome analyses identify key cellular factors associated with HIV-1-associated neuropathogenesis in infected men.

Authors:  Narasimhan J Venkatachari; Siddhartha Jain; Leah Walker; Shalmali Bivalkar-Mehla; Ansuman Chattopadhyay; Ziv Bar-Joseph; Charles Rinaldo; Ann Ragin; Eric Seaberg; Andrew Levine; James Becker; Eileen Martin; Ned Sacktor; Velpandi Ayyavoo
Journal:  AIDS       Date:  2017-03-13       Impact factor: 4.177

7.  Factors related to HIV-associated neurocognitive impairment differ with age.

Authors:  Gary B Fogel; Susanna L Lamers; Andrew J Levine; Miguel Valdes-Sueiras; Michael S McGrath; Paul Shapshak; Elyse J Singer
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

8.  Critical Role of Beclin1 in HIV Tat and Morphine-Induced Inflammation and Calcium Release in Glial Cells from Autophagy Deficient Mouse.

Authors:  Jessica Lapierre; Myosotys Rodriguez; Chet Raj Ojha; Nazira El-Hage
Journal:  J Neuroimmune Pharmacol       Date:  2018-05-11       Impact factor: 4.147

9.  Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV.

Authors:  Stephen Correia; Ronald Cohen; Assawin Gongvatana; Skye Ross; James Olchowski; Kathryn Devlin; Karen Tashima; Bradford Navia; Suzanne Delamonte
Journal:  J Neuroimmunol       Date:  2013-09-27       Impact factor: 3.478

10.  Characterization of neuropathology in the HIV-1 transgenic rat at different ages.

Authors:  William C Reid; Wael G Ibrahim; Saejeong J Kim; Frank Denaro; Rafael Casas; Dianne E Lee; Dragan Maric; Dima A Hammoud
Journal:  J Neuroimmunol       Date:  2016-02-03       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.